Prasugrel

Chemical formula: C₂₀H₂₀FNO₃S  Molecular mass: 373.441 g/mol  PubChem compound: 6918456

Therapeutic indications

Prasugrel is indicated for:

Prevention of atherothrombotic events in acute coronary syndrome undergoing percutaneous coronary intervention (PCI)

Population group: only adults (18 - 65 years old)

Prasugrel, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Prasugrel is contraindicated in the following cases:

Severe hepatic impairment (Child Pugh class C)

Hepatic failure stage IV

History of stroke, history of transient ischaemic attack (TIA)

at least one of
H/O: CVA
History of transient ischemic attack

Active pathological bleeding

Bleeding

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2021: EFFIENT Film-coated tablet
Summary of Product Characteristics (SPC) 2019: EFIENT Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈